The Copaxone News Channel
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
March 2005   
June 2005   
July 2005   
August 2005   
October 2005   
November 2005   
December 2005   
January 2006   
February 2006   
May 2006   
June 2006   
August 2006   
October 2006   
November 2006   
December 2008   
January 2013   
May 2013   
June 2013   
July 2013   
September 2013   
October 2013   
November 2013   
November 2014   
December 2014   
January 2015   
March 2015   
April 2015   
May 2015   
July 2015   
February 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Relapsing MS Treatment Now Available in Japan

Copaxone, marketed by Takeda, is already approved for use in some 50 countries

Takeda Pharmaceutical Co. Ltd., a pharmaceutical company based in Osaka, Japan, recently announced that a widely approved drug treatment for the prevention of relapses in multiple sclerosis (MS) is now available in Japan as well.

Copaxone, (glatiramer acetate; 20 mg daily subcutaneous injection), developed by Teva Pharmaceuticals Industries Ltd., is an immunomodulatory drug designed to act as a decoy for the exacerbated immune system in MS, reducing inflammation in the central nervous system. The drug is a random polymer of four basic amino acids found in myelin. Copaxone has been shown to reduce the relapse frequency in patients with remitting or relapsing MS.

MS is estimated to affect approximately 18,000 people in Japan. In 2009, the Japanese Ministry of Health, Labour and Welfare (MHLW) gave orphan drug designation to Copaxone, a special status given to drugs for the treatment of rare conditions. In the following year, MHLW supported the development of Copaxone as an “unapproved drug highly needed in medical care.” Takeda and Teva entered into a license agreement for the commercialization of Copaxone in Japan in 2013, and Takeda obtained approval for a new drug application (NDA) for Copaxone in September 2015, enabling its sale and marketing.

“Copaxone, one of the most frequently used drugs in multiple sclerosis, is approved in more than 50 countries worldwide, and is expected to represent a new treatment option for Japanese patients,” said Dr. Masato Iwasaki, director and president, Japan Pharma Business Unit of Takeda, in a press release. “Takeda will continue to be committed to delivering drugs for diseases that remain as high unmet medical needs for both patients and physicians.”

Copaxone has been approved for use in the United States, Canada, Mexico, Australia, Russia, Israel, the EU, and other countries.

MS is an autoimmune disease in which the myelin sheath that covers and protects neurons is destroyed by the body’s own immune system, a process known as demyelination, leading to irreversible neurological disability and motor function impairment. MS patients may experience relapses (disease exacerbations or flare-ups), which are characterized by the worsening of neurological function.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length